bioRxivBiochemistryPreprint
Computationally Designed RNA Aptamers Enable Selective Detection of FUS Pathology in ALS
Elsa ZaccoiD, Martina GilodiiD, Abigail Dos Santos, Alexandros ArmaosiD, Rachel James, Francesco Di PalmaiD, Fergal M. WaldroniD, Marco Scotto, Jakob RupertiD, Vlad Korobeynikov, Neil A. ShneideriD, Mathew H. HorrocksiD, Jenna M. GregoryiD, Gian Gaetano TartagliaiD
Abstract
FUS is an RNA/DNA-binding protein whose mislocalization and aggregation are defining pathological features of amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD). Detecting pathological FUS assemblies remains challenging, as antibody-based approaches are frequently limited by epitope masking, conformational heterogeneity, and cross-reactivity with physiological FUS pools. Here we apply rationally designed RNA aptamers to selectively recognize FUS across soluble and aggregated states. The aptamers bind solvent-exposed RNA-binding regions of FUS with low-nanomolar affinity and adopt stable hairpin conformations that support high specificity. In cultured cells expressing the ALS-associated p.P525L FUS mutation, the aptamers detect cytoplasmic and nuclear FUS assemblies that are frequently missed by commercial antibodies and show reduced recognition of FUS-containing protein complexes. Using super-resolution imaging, the aptamers enable visualization of early FUS aggregation intermediates that are inaccessible to conventional amyloid dyes. In post-mortem brain tissue from individuals with FUS-ALS, aptamer staining selectively labels pathological FUS while sparing normal nuclear FUS, revealing prominent nuclear and nucleolar pathology that is poorly resolved by antibody-based methods. Together, these findings establish RNA aptamers as sensitive and selective probes for pathological FUS and uncover previously underappreciated features of FUS aggregation in ALS. This work highlights the value of nucleic-acid-based recognition tools for interrogating protein misfolding and neurodegenerative disease pathology.
- organism: human
- assay: proteomics
- research focus: host-pathogen & immune response
- approach: experimental assay
- Citations
- 2
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Frontotemporal dementia-like disease progression elicited by seeded aggregation and spread of FUS
Sonia Vazquez‐Sanchez, Britt Tilkin, … Sandrine Da Cruz·Molecular NeurodegenerationPeer-reviewed·Jun 11, 2024
- Mutation of the ALS/FTD-associated RNA-binding protein FUS alters axonal cytoskeletal organisation
Francesca W. van Tartwijk, Lucia C. S. Wunderlich, … Clemens F. Kaminski·Journal of NeurosciencePeer-reviewed·May 1, 2024
- Targeting FUS-ALS aggregation with Proteasome Inhibitors
Amal Younis, Kanar Yassen, … Reut Shalgi·bioRxiv·Sep 17, 2024
- A structure-guided antibody detects SOD1 oligomers in diverse ALS genotypes.
Smriti Sangwan, Hannah E. Rieder, … David S Eisenberg·bioRxiv·May 5, 2025
- RNA aptamer reveals nuclear TDP-43 pathology is an early aggregation event that coincides with STMN-2 cryptic splicing and precedes clinical manifestation in ALS
Holly Spence, Fergal M. Waldron, … Jenna M. Gregory·bioRxiv·Oct 24, 2023
- Synaptic accumulation of FUS triggers age-dependent misregulation of inhibitory synapses in ALS-FUS mice
Sonu Sahadevan, Katharina Hembach, … Magdalini Polymenidou·bioRxiv·Jun 10, 2020